Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 18/20 | 0.35 |
| ▸ | NTRK3 | Q16288 | 6/20 | 0.35 |
| ▸ | NTRK2 | Q16620 | 6/20 | 0.35 |
| ▸ | AXL | P30530 | 1/20 | 0.34 |
| ▸ | FYN | P06241 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1441011 | 1.00 | NTRK1 (0.35) | NTRK1NTRK3NTRK2AXLFYN | |
| SCHEMBL1440944 | 0.77 | CDK2 (0.39) | NTRK1NTRK3NTRK2AXLFYN | |
| SCHEMBL1442102 | 0.77 | PIM1 (0.36) | NTRK1NTRK3NTRK2AXLFYN | |
| SCHEMBL1442100 | 0.77 | PIM1 (0.36) | NTRK1NTRK3NTRK2AXLFYN | |
| SCHEMBL1440946 | 0.77 | CDK2 (0.39) | NTRK1NTRK3NTRK2AXLFYN | |
| SCHEMBL23148335 | 0.75 | NTRK1 (0.43) | NTRK1NTRK3NTRK2AXL | |
| SCHEMBL23148336 | 0.75 | NTRK1 (0.43) | NTRK1NTRK3NTRK2AXL | |
| SCHEMBL20967402 | 0.74 | TGFBR2 (0.49) | NTRK1NTRK2AXLFYN | |
| SCHEMBL10276915 | 0.72 | NTRK1 (0.38) | NTRK1NTRK3FYN | |
| SCHEMBL1441727 | 0.72 | NTRK1 (0.38) | NTRK1NTRK3FYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8865726-B2 | Substituted pyrazolo[1,5-a]pyrimidine compounds as mTOR inhibitors | ARRAY BIOPHARMA INC. (US) | 2014-10-21 | — | — | US | disclosed |
| US-20120178715-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2012-07-12 | — | — | US | disclosed |
| WO-2011029027-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2011-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178715-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS | MTOR, RICTOR, EIF4EBP1 | NTRK1 3204/4885NTRK3 2720/4885NTRK2 3626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.